Athira Pharma, Inc. (ATHA)
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
$17.87M
Dr. Mark J. Litton M.B.A., MBA, Ph.D.
34.00
Bothell, WA
Sep 18, 2020
-0.16
$-2.97
3.06
3.97
-6,850.91%
-0.16
-0.00
0.22
11.28
3.97
-101.98%
-95.53%
Similar stocks (6)
Nuvation Bio Inc.
NUVB
Instil Bio, Inc.
TIL
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
NextCure, Inc.
NXTC
ETF Exposure (17)
iShares Micro-Cap ETF
IWC
0.00485%
Dimensional U.S. Targeted Value ETF
DFAT
6.7872e-4%
Dimensional U.S. Small Cap ETF
DFAS
2.1164000000000003e-4%
Dimensional US Sustainability Core 1 ETF
DFSU
2.1146999999999998e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
2.813e-5%
Dimensional U.S. Equity ETF
DFUS
1.47e-6%
iShares MSCI USA Small-Cap Multifactor ETF
SMLF
0%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (6)
Nuvation Bio Inc.
NUVB
Instil Bio, Inc.
TIL
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
NextCure, Inc.
NXTC
ETF Exposure (17)
iShares Micro-Cap ETF
IWC
0.00485%
Dimensional U.S. Targeted Value ETF
DFAT
6.7872e-4%
Dimensional U.S. Small Cap ETF
DFAS
2.1164000000000003e-4%
Dimensional US Sustainability Core 1 ETF
DFSU
2.1146999999999998e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
2.813e-5%
Dimensional U.S. Equity ETF
DFUS
1.47e-6%
iShares MSCI USA Small-Cap Multifactor ETF
SMLF
0%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%